Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.

Grade IV glioblastoma is characterized by increased kinase activity of epidermal growth factor receptor (EGFR); however, EGFR kinase inhibitors have failed to improve survival in individuals with this cancer because resistance to these drugs often develops. We showed that tumor necrosis factor-α (TNFα) produced in the glioblastoma microenvironment activated atypical ...
protein kinase C (aPKC), thereby producing resistance to EGFR kinase inhibitors. Additionally, we identified that aPKC was required both for paracrine TNFα-dependent activation of the transcription factor nuclear factor κB (NF-κB) and for tumor cell-intrinsic receptor tyrosine kinase signaling. Targeting aPKC decreased tumor growth in mouse models of glioblastoma, including models of EGFR kinase inhibitor-resistant glioblastoma. Furthermore, aPKC abundance and activity were increased in human glioblastoma tumor cells, and high aPKC abundance correlated with poor prognosis. Thus, targeting aPKC might provide an improved molecular approach for glioblastoma therapy.
Mesh Terms:
Animals, Carcinogenesis, Drug Delivery Systems, Enzyme-Linked Immunosorbent Assay, Epidermal Growth Factor, ErbB Receptors, Erlotinib Hydrochloride, Flow Cytometry, Fluorescent Antibody Technique, Glioblastoma, Humans, Immunoblotting, Immunohistochemistry, Immunoprecipitation, Kaplan-Meier Estimate, Mice, NF-kappa B, Paracrine Communication, Protein Kinase C, Quinazolines, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction, Tumor Necrosis Factor-alpha
Sci Signal
Date: Aug. 12, 2014
Download Curated Data For This Publication
217709
Switch View:
  • Interactions 1